We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NXPI:NASDAQNXP Semiconductors N.V. Analysis

Data as of 2026-05-19 - not real-time

$292.35

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

NXP Semiconductors posted a solid 12% year‑over‑year revenue increase, driven by automotive and industrial demand, and delivered earnings that beat expectations, lifting the stock roughly 11% on the day. Operating margins remain robust at around 47% and free cash flow exceeds $3 billion, supporting a stable dividend payout of 1.4% with a 38% payout ratio. The technical picture is mixed: price sits above the 20‑day SMA and the 50‑day SMA, indicating a bullish trend, yet the MACD histogram is negative and volume is on a downtrend, suggesting short‑term pressure as the stock approaches its resistance near $306. The DCF model values the company at roughly $235, well below the current market price of $292, implying a modest overvaluation despite an industry‑average PE that is higher than NXPI’s. With a beta of 1.58 and 30‑day volatility above 70%, the stock is sensitive to market swings, but the recent earnings beat, upgraded analyst target to $300, and continued secular growth in automotive semiconductors provide a compelling upside of about 2‑3%.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Negative MACD histogram indicating short‑term bearish momentum
  • Decreasing volume trend reducing liquidity confidence
  • Proximity to resistance level limiting immediate upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong Q1 earnings beat and raised analyst price target to $300
  • Sustained revenue growth and high operating margins
  • Modest upside potential relative to current price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Secular demand from automotive and IoT segments
  • Solid free cash flow supporting dividend sustainability
  • Competitive positioning with a diversified product portfolio

Key Metrics & Analysis

Financial Health

Revenue Growth12.20%
Profit Margin21.03%
P/E Ratio27.9
ROE25.81%
ROA9.64%
Debt/Equity103.99
P/B Ratio6.8
Op. Cash Flow$3.0B
Free Cash Flow$3.1B
Industry P/E38.0

Technical Analysis

TrendBullish
RSI64.7
Support$224.79
Resistance$306.62
MA 20$279.81
MA 50$232.07
MA 200$224.71
MACDBearish
VolumeDecreasing
Fear & Greed Index89.32

Valuation

Fair Value$235.48
Target Price$300.13
Upside/Downside2.66%
GradeOvervalued
TypeGrowth
Dividend Yield1.39%

Risk Assessment

Beta1.59
Volatility74.59%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.